Stablepharma Ltd – Invitation to Tender
Whitepaper highlighting the economic and environmental benefits of fridge-free vaccines
Company Background
Vaccines are temperature-sensitive products that experience a loss in efficacy and potency if exposed to temperatures which are either too hot or too cold.
Our vision is to save lives and reduce global wastage by making fridge-free vaccines a reality, a world’s first. We use our StablevaX™ technology to reformulate and thermo-stabilise approved, existing and new vaccines in partnership with vaccine manufacturers.
Through this, we eliminate the need for the cold-chain, and reduce wastage, costs, and carbon emissions. StablevaX™ technology eliminates the need for the refrigeration/cold-chain entirely, extending shelf-life and enabling strategic stockpiling.
The majority of vaccines require constant refrigeration between 2-8°C. The World Health Organisation (WHO) estimates that 50% of the world’s vaccines are rendered useless each year due to failings of the existing refrigeration processes (known as the ‘The Cold Chain’) used for delivery and storage.
Our founder Dr Bruce Roser first identified and patented the process of using trehalose to achieve a state of ‘suspended animation’ in a sugar glass, to thermally stabilise a range of vaccines. Trehalose is now commonly used in many pharmaceutical products and is observed naturally in some living organisms, most notably in the case of the “resurrection” plant.
We target a significant addressable and expanding global market with the global human vaccine market exhibiting a revenue of USD 74.12bn in 2024 and forecasts suggesting a market revenue of USD 88.61bn by 2029 (Statista 2024).
As the WHO state that up to 50% of those vaccines are compromised by failures with the cold chain, we see demand and product acceptance being driven by payers, seeking a solution to wastage, and by competing manufacturers who will wish to leverage our technology platform to differentiate their products.
This particular data-gathering project was quickly identified as being an important contributor to planning growth and specifically securing new vaccine manufacturing partners.
We are confident that the data will support both the cost-effectiveness and the environmental benefit of fridge-free, extended shelf-life vaccines in HICs.
The data will complement a previous study we commissioned with EU healthcare professionals that produced a 79% positive response in support of the need for thermostable vaccines.
A report emphasising the value of thermostable vaccines will allow us to effectively engage key stakeholders, including commercial distribution partners, NGOs and current or prospective investors.
This work will be part funded through the Innovate Growth Support Scale Up Services
Company website at; www.stablepharma.com
Introduction video at https://vimeo.com/694008731
Requirement
Stablepharma is seeking proposals from qualified suppliers to produce a comprehensive whitepaper highlighting the economic and environmental benefits of fridge-free vaccines, specifically focusing on high-income countries.
This whitepaper will play a crucial role in reinforcing the value of thermostable vaccines, which can be formulated using our proprietary StablevaX™ technology, which eliminates the need for cold-chain logistics, reduces vaccine wastage, and offers significant cost and carbon savings.
Key Deliverables
- A 1-page outline of the whitepaper.
- An 8-page final whitepaper in PDF format.
- An 8-slide communications deck with a supporting appendix.
- Key project documents, including meeting materials, a TLR report, and an analysis plan.
Expected Outcomes
- A detailed and compelling whitepaper that effectively demonstrates the economic and environmental benefits of fridge-free vaccines.
- Supporting materials that will facilitate the dissemination of the whitepaper to stakeholders.
Services Required
- Phase 1: Targeted Literature Review (TLR):
o Conduct a thorough literature review to establish a knowledge base for the analysis.
o Compile and assess existing materials, including Stablepharma data, to inform the whitepaper.
- Phase 2: Data Analysis and Extrapolation:
o Use vaccine sales data to analyse and extrapolate findings on the economic and environmental impact of fridge-free vaccines.
o Optionally extend the analysis to other treatment modalities, depending on the literature review findings.
- Phase 3: Whitepaper Development:
o Draft, revise, and finalise a compelling whitepaper that effectively communicates the analysis results.
o Create a communications deck to support the dissemination of the whitepaper.
Deliverable Timescale
(Please note; Deliverables are based on an expected October 2024 start date)
- Scope & Gather: 3 weeks
- Define & Analyse: 3 weeks
- Outline & Produce: 4 weeks
Indicative Budget
- Phase 1: Scope and Gather: £26,000 – £29,000
- Phase 2: Define and Analyse: £17,000 – £20,000
- Phase 3: Outline and Produce: £6,000 – £8,000
- Total: £49,000 – £57,000
Evaluation Criteria
Quotations will be assessed and scored on the following criteria:
- Quality and Technical Merit – do your services offered fit the scope of the project. • Does the supplier have the required knowledge and experience to deliver the project? • Delivery Timescale – can the supplier meet the timescales/deadline?
- Cost and Value for Money – Is the price good value for money- this will not necessarily be the cheapest option.
Submission & Contacts
Please submit your tender by the deadline of 5 pm on October the 10th 2024 by e mail in PDF format to;
Tom Rosenfeld trosenfeld@stablepharma.com
and
Nick Child nchild@stablepharma.com
4 Queen Street Bath UK BA1 2HE
Tel 01225 581 220
Tender Publish date 25 September 2024